| |
| |
|
| Insider
Information: |
Meltz Mark A |
| Relationship: |
|
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
0 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Audentes Therapeutics, Inc. |
BOLD |
SVP, General Counsel |
2020-01-15 |
0 |
2019-03-28 |
0 |
Premium* |
|
|
Kinnate Biopharma Inc. |
KNTE |
|
2024-04-03 |
0 |
2022-09-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
11 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KNTE |
Kinnate Biopharma Inc. |
COO GENERAL COUNSEL SECRETARY |
• – – |
2024-04-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(27,578) |
0 |
0 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
COO GENERAL COUNSEL SECRETARY |
• – – |
2024-03-01 |
4 |
D |
$2.59 |
$1,445 |
D/D |
(558) |
27,578 |
0 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
COO General Counsel Secretary |
• – – |
2023-12-01 |
4 |
D |
$2.25 |
$1,217 |
D/D |
(541) |
28,136 |
0 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
COO General Counsel Secretary |
• – – |
2023-09-01 |
4 |
D |
$2.35 |
$1,271 |
D/D |
(541) |
28,677 |
0 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
COO General Counsel Secretary |
• – – |
2023-06-01 |
4 |
D |
$4.30 |
$2,326 |
D/D |
(541) |
29,218 |
0 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
COO General Counsel Secretary |
• – – |
2023-03-01 |
4 |
D |
$5.21 |
$3,324 |
D/D |
(638) |
27,286 |
0 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
COO General Counsel Secretary |
• – – |
2022-12-01 |
4 |
D |
$7.75 |
$4,193 |
D/D |
(541) |
27,924 |
0 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
COO General Counsel Secretary |
• – – |
2022-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
28,465 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
SVP, General Counsel |
• – – |
2020-01-15 |
4 |
D |
$60.00 |
$1,962,300 |
D/D |
(32,705) |
0 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
SVP, General Counsel |
• – – |
2019-12-12 |
4 |
D |
$59.37 |
$274,764 |
D/D |
(4,628) |
32,705 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
SVP, General Counsel |
• – – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
37,333 |
37,333 |
0 |
- |
|
11 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
